Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals (BLCM) PT Lowered to $25 at Citi Following Rimiducid Activation Switch

March 15, 2018 6:58 AM EDT

Citi lowered its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $25.00 (from $27.00) while maintaining a Buy rating following the company's announced details of the first patient to receive the Rimiducid activation switch. The company is still investigating what happened to the cells, and noted... More